Page results
-
Our vaccination centre at the Business Design Centre, Islington, closed on Monday 10 January.
-
Health secretary Matt Hancock visited University College Hospital yesterday to see for himself our post-Covid-19 service set up to help survivors of the virus with their long-term recovery.
-
The Royal London Hospital for Integrated Medicine (RLHIM) is a centre for evidence-based practice, education and research, specialising in chronic and complex medical conditions. Our mission is to provide a person-centred, holistic approach, including self-care, in order to help people with chronic and complex medical conditions live well and feel better. Our approach considers the whole person and their environment in the quest for optimal health and wellbeing. In order to achieve this, we provide a combination of lifestyle strategies, medical, physical and psychological treatment, as well as advice on safe and appropriate use of complementary therapies. We also deliver and encourage self-care approaches which can continue to be used by patients after discharge. All RLHIM services are outpatient-based and are staffed by experienced healthcare professionals.
-
Information for patients from overseas visiting UCLH hospitals.
-
From the 23rd January, there will be a staggered rollout of the Tandem t:slim™ 7.7 Control IQ software.
-
Experts from across the world, led by UCLH and UCL clinicians and scientists, have created a framework to guide the introduction of new and advanced robots for surgical procedures.
-
This Mobile Health Clinic has been extensively refurbished and fitted with a new digital portable x-ray camera and modern technologies to speed patient diagnoses and treatment of infectious diseases that will be powered on green energy.
-
Information for service users about the RESPOND service for refugees and asylum seekers.
-
The haematology and critical care services in our flagship University College Hospital Grafton Way Building are now open.
-
Update about our hospital on Gray's Inn Road
File results
-
FOI/2022/0214 - Prostate Cancer (Summary Funding and costs of Xtandi (Enzalutamide) trial: NCT00974311) Xtandi (Enzalutamide) trial, NCT00974311
-
FOI/2022/0217 - Medications for dermatological conditions
-
FOI/2022/0221 - Asthma medications
-
FOI/2022/0223 - Policies/ procedures for management of patients with chest pain
-
FOI/2022/0224 - Procurement for physiotherapy, occupational therapy, pharmacy, radiography, speech and language therapy and sterile services
-
FOI/2022/0226 - Treatments for Haemophilia A
-
FOI/2022/0227 - Number of cancer trackers and cancer MDT co-ordinators at Trust
-
FOI/2022/0230 - Fabry, Gaucher and Pompe diseases drug treatments
-
FOI/2022/0232 - Number of patients who have died while waiting for elective care
-
FOI/2022/0233 - Diagnosis/ treatment of epilepsy, dravet syndrome, lennox gastaut syndrome and tuberous sclerosis complex